Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients

European Journal of Neurology

Volumn 20, Issue 7, 2013, Pages 1060-1067

  Romeo, M ^a   Martinelli Boneschi, F ^a   Rodegher, M ^a   Esposito, F ^a   Martinelli, V ^a   Comi, G ^a,b   Colombo, B ^a   Moiola, L ^a   Rossi, P ^a   Poggi, A ^a   Radaelli, M ^a   Perego, E ^a   Straffi, L ^a   Liberatore, G ^a   Dalla Libera, D ^a   De Feo, D ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Glatiramer acetate; Interferon beta; MRI; Multiple sclerosis; Relapse; Treatment response

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; AGE DISTRIBUTION; AGED; ANNUALIZED RELAPSE RATE; ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; DRUG RESISTANCE; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROIMAGING; PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84879022224     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12119     Document Type: Article

References (24)

1. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta 1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.Lancet 1998; 352: 1498-1504.
2. Johnson KP, Brooks BR, Cohen JA, et al. The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45: 1268-1276.
3. Comi G, Filippi M, Wolinsky JS, European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297.
4. Wolansky L, Cook S, Skurnick J, et al. Betaferon vs. copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): announcement of final primary study outcome. Mult Scler 2007; 13: P207.
5. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet 2008; 7: 903-914.
6. ® Efficacy Yielding Outcomes of a New Dose) study. Neurology 2008; 70 (11; LateBreaking Science Supplement): S004.
7. Trojano M, Russo P, et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis. Mult Scler 2006; 12: 578-585.
8. Rio J, Rovira A, Tintorè M, et al. Relationship between MRI lesions activity and response to IFN-β in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484.
9. Rio J, Nos C, Tintorè M, et al. Defining the response to interferon beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
13. Fleiss JL. Statistical Methods for Rates and Proportions, 2nd edn. New York: John Wiley, 1981.
14. Río J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 2011; 24: 230-237.
15. Villoslada P, Oksenberg JR, Rio J, Montalban X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2004; 62: 1653.
16. Fromont A, Debouverie M, Le Teuff G, Quantin C, Binquet C, Moreau T. Clinical parameters to predict response to interferon in relapsing multiple sclerosis. Neuroepidemiology 2008; 31: 150-156.
17. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009; 16: 1202-1209.
18. Sylvia Lawry Centre for Multiple Sclerosis Research. Available at: http://www.slcmsr.net/ (accessed 15/02/2013)
19. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind placebo controlled trial. Lancet 2009; 374: 1503-1511.
20. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002; 59: 998-1005.
21. Milanese C, Begni E, Giordano L, La Mantia L, Mascoli N, Confalonieri P. A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. Neurol Sci 2005; 26: S171-S173.
22. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining Interferon β response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.
23. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
24. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 2010; 75: 302-309.